BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a highly prevalent disease whose sufferers consume a large amount of resources. Among community-dwelling Medicare beneficiaries, 12% reported that they had COPD in 2002. For clinicians, differentiating COPD from asthma may be difficult, but among patients with COPD and asthma, approximately 20% have both conditions. The economic impact of concomitant asthma and COPD is potentially large but has not been studied.
OBJECTIVE: To assess the cost burden of asthma in patients with COPD in a Medicare Advantage population.
METHODS:
We reviewed the database of a large health plan that contained information from more than 30 distinct plans covering approximately 25 million members. We identified Medicare beneficiaries aged 40 years or older with medical and pharmacy benefits and medical claims with International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes for COPD or asthma over a 1-year identification period (calendar year 2004). We assigned patients to 2 cohorts based on diagnoses on medical claims (any diagnosis field) during 2004; the COPD cohort had at least 1 medical claim for COPD, and the COPD + asthma cohort had at least 1 claim for COPD and at least 1 claim for asthma. A patient's index date was the first date during 2004 in which there was a medical claim with a diagnosis code for COPD or asthma. To confirm diagnosis, each patient was required to have at least 1 additional claim for COPD (COPD cohort) or at least 1 claim for COPD and at least 1 claim for asthma (COPD + asthma cohort) during the 24-month period from 12 months before through 12 months after the index date. We excluded patients who (1) were not continuously enrolled during the 12 months before and after the index date and (2) did not have at least 1 pharmacy claim for a drug of any type (to verify pharmacy benefits). Outcome measures included the use of emergency room (ER) and hospital services, and cost (net provider payment after subtraction of member cost share), categorized as all-cause, non-respiratory, and respiratory-related. ER use and inpatient hospital stays were identified using place-of-service codes. A minimum of 2 consecutive dates of service (length of stay [LOS] of at least 1 day) was required to indicate an inpatient hospitalization. An LOS of at least 1 day was required to distinguish inpatient services from other services (e.g., procedures or tests) reported on claims with an inpatient place of service. Multivariate analyses adjusted for age, gender, census region, and Charlson Comorbidity Index (CCI). Ordinary least squares regression was used to predict respiratory-related total health care costs, and logistic regression was used to predict the occurrence of at least 1 acute event, defined as use of either an ER or an inpatient hospital. All 2-way interactions were considered, and only those with significant results were included in the models. All reported P values were 2-sided with a 0.05 significance level.
RESULTS: During 2004, 68,532 individuals within the database were enrolled in a Medicare Advantage plan. After application of the other inclusion criteria, we excluded approximately 11% of the patients who did not have 1 pharmacy claim of any type. There were 8,086 patients (11.8%) who had at least 1 medical claim with diagnosis codes for COPD and at least 1 other medical claim for either COPD or asthma and were continuously enrolled for at least 24 months. The COPD + asthma cohort numbered 1,843 patients (22.8%), and the COPD cohort numbered 6,243 patients (77.2%). Compared with COPD patients without asthma, patients with COPD + asthma were slightly younger, and a higher proportion was female. There were differences between the 2 cohorts in geographic distribution, and the COPD + asthma cohort had a higher disease severity with a mean CCI score of 2. 
What is already known about this subject R E S E A R C H
M ore than 11.6 million adults in the United States have been diagnosed with chronic obstructive pulmonary disease (COPD), and it has become the 4th leading cause of death among U.S. adults.
1 The costs associated with COPD are substantial. [1] [2] [3] Among community-dwelling Medicare beneficiaries in 2002, 12% reported that they had COPD with an average annual spending on prescription drugs of $2,359 and medical spending of $21,488.
2 Emergency room (ER) visits and hospitalizations for COPD are common, particularly among the elderly. In 2004, approximately 65% of patients discharged with diagnoses of COPD were aged 65 years and older.
1 Among patients hospitalized with COPD exacerbations, approximately 50% experienced rehospitalization within 24 months. 4 As a result, health care expenditures for Medicare beneficiaries with COPD were 2.4 times those of all-aged Medicare beneficiaries in 1992. 5 While therapies that improve lung function have been shown to reduce health care spending, managing patients with COPD has become a major challenge for health care professionals, public and private health care payers, and policymakers. [6] [7] [8] [9] Further adding to this challenge is managing COPD in the presence of other chronic lung diseases such as asthma. In 2004, more than 3.3 million individuals aged 65 years and older reported that they had been told by health care professionals that they had asthma. 10 Between 1995 and 2004, the rates of hospitalization with asthma listed as the primary diagnosis declined within all age groups except those aged 65 years and older. While differentiating between COPD and asthma may be difficult for clinicians, there has been increased awareness that asthma and COPD coexist in approximately 20% of COPD patients.
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According to a 20-year study, patients with active asthma were 12 times more likely to develop COPD during their lifetimes than patients without asthma.
12 While the pathogeneses of asthma and COPD differ, both are characterized by bronchial obstruction and airway inflammation, which often lead to ER visits and hospitalizations. In a 1992 study of Medicare beneficiaries, patients with COPD and comorbid conditions such as pneumonia or congestive heart failure incurred higher expenditures (1.6 and 2.1 times higher, respectively) than similarly aged Medicare patients with COPD and without these comorbidities. 5 However, to our knowledge, little has been published about the impact of concomitant COPD and asthma in the elderly population.
The Centers for Medicare & Medicaid Services (CMS) require that health plans that offer Medicare Advantage plans and prescription drug plans include quality assurance programs such as chronic care improvement and medication therapy management programs. 13 Quality assurance and disease management programs are costly to implement.
14 A common approach has been to target various intervention intensity levels based on cost patterns within a population, whereby the most costly patients receive the most intensive interventions, and the less costly patients receive the less intensive interventions. 15 To do so, identifying a costly subset with characteristics that may be effectively intervened upon is vital. Therefore, because of the high prevalence of both COPD and asthma, we conducted a study to identify the cost burden of concomitant COPD and asthma within a Medicare Advantage population. (Table 1) . 16 The index date was the date of the first medical or hospital claim during the identification period with an ICD-9-CM code for asthma or COPD. A 12-month period before the index date was used to identify pre-index characteristics, and a 12-month period after the index date was used to identify health care utilization and cost outcomes. Continuous enrollment was defined as enrollment in the health plan during the 12 months before the index date (pre-index period) through the 12 months after the index date (post-index period). The observation period for each patient was defined as the 24-month period from the beginning of the pre-index period to the end of the post-index period ( Figure 1 ). To ensure that all
■■ Methods

Data Source
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• To our knowledge, this is the first study that examined the burden of concomitant COPD and asthma among Medicare beneficiaries. After adjustment for demographics and comorbidities, respiratory-related health care costs were 37.1% higher in patients with COPD and asthma than in patients with COPD and no evidence of asthma.
• Respiratory-related pharmacy costs were a relatively small part of total respiratory-related health care costs, approximately 5.7% for the COPD cohort and 8.8% for the COPD + asthma cohort.
• Respiratory-related costs accounted for 22.0% of total health care costs for the COPD cohort and 28.7% for the COPD + asthma cohort.
What this study adds
study patients had a pharmacy benefit so that we could accurately measure pharmacy claims cost, each patient was required to have at least 1 pharmacy claim for any medication during the observation period.
Patient Selection
COPD Cohort
Each patient (aged 40 years and older) had to have at least 1 medical claim with an ICD-9-CM code for COPD (491.xx for chronic bronchitis, 492.xx for emphysema, or 496.xx for chronic airway obstruction not classified elsewhere) during the identification period (calendar year 2004). The index date was defined as the date of the first medical claim with a COPD diagnosis during the identification period. To confirm diagnosis, each patient was required to have at least 1 additional medical claim with an ICD-9-CM code for COPD during the 24-month observation period (from 12 months before through 12 months after the index date). Any patient who had a medical claim with an ICD-9-CM code for asthma during the observation period was included in the COPD + asthma cohort if the patient met the sampling requirements for that cohort, or excluded from the study if the patient did not meet the sampling requirements for the COPD + asthma cohort.
COPD + Asthma Cohort
Each patient (aged 40 years and older) had to have at least 1 medical claim with an ICD-9-CM code for COPD and at least 1 medical claim for asthma (493.0x, 493.1x, 493.8x, 493.9x) during the identification period. The first medical claim for each diagnosis was identified, and the earlier of the 2 dates within the identification period was selected as the index date. To confirm diagnoses, each patient was required to have at least 1 additional medical claim for COPD and at least 1 additional claim for asthma during the observation period. If a medical claim with an ICD-9-CM code for COPD and asthma (493.2x) was used during the identification period, the criterion for each disease was met, and the date of that claim was used as the index date. However, to qualify for the study, these patients still had to have either (1) at least 1 additional claim with an ICD-9-CM code for COPD and asthma (493.2x) or (2) at least 1 additional medical claim for COPD and at least 1 additional claim for asthma within the observation period.
Outcome Variables
The primary outcomes of interest were (1) respiratory-related health care costs and (2) occurrence of an acute event, defined as a respiratory-related ER visit or hospitalization. Place-of-service codes were used to identify office visits, ER visits, and inpatient hospitalizations. A minimum of 2 consecutive dates of service (length of stay [LOS] of at least 1 day) was required to indicate an inpatient hospitalization. An LOS of at least 1 day was required to distinguish inpatient services from other services (e.g., procedures or tests) reported on claims with an inpatient place of service.
Pharmacy, medical, and total health care costs were reported as respiratory-related, not respiratory-related, and all-cause. The IHCIS dataset includes standardized costs that reflect net provider payments after subtraction of member cost-share. Pharmacy claims for all respiratory medications were considered respiratory-related (Table 1) . Medical claims with respiratory diagnoses listed as primary diagnoses were considered respiratory-related (ICD-9-CM diagnosis codes 460.xx-519.xx). Outcome measures derived from health care utilization claims included outpatient physician visits, all other outpatient visits, ER visits, hospitalizations with an LOS of at least 1 day, total inpatient days per patient, and ER and/or hospitalizations with an LOS of at least 1 day. If a patient had an ER visit that advanced to a hospitalization, it was considered a hospitalization. If a patient had an ER visit that did not advance to a hospitalization, it was considered an ER visit.
The number of patients who received outpatient treatment for acute exacerbations of COPD was reported. Outpatient treatment for a COPD exacerbation was defined as (1) at least 1 medical claim for an outpatient physician visit with ICD-9-CM code for COPD as the primary diagnosis and (2) at least 1 pharmacy claim with a National Drug Code (NDC) number 17 for a 14-day (or fewer) course of an oral corticosteroid or antibiotic, either of which was filled within 2 days of the outpatient physician visit.
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If the concomitant ICD-9-CM code for COPD + asthma (493.2x) was used, it was considered a COPD diagnosis for this metric.
Other study variables included age, gender, geographic region, and pre-index characteristics, including Charlson Comorbidity Index (CCI, defined in the text that follows) scores, the individual CCI components, and select other comorbid conditions. 19 The CCI contains 19 categories of comorbidities, defined using ICD-9-CM diagnosis codes. Each category has an associated weight based on adjusted risk of 1-year mortality. The overall score reflects the cumulative increased likelihood of 1-year mortality. A higher score reflects a more severe comorbidity burden. For this analysis, we used an adapted version of the clinical index developed by Charlson and her colleagues, which is based on medical record review and contains 17 categories of comorbidities.
20 These categories include myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, rheumatologic disease, peptic ulcer disease, moderate or severe liver disease, diabetes with complications, hemiplegia or paraplegia, renal disease, malignant neoplasms, metastatic solid tumors, and acquired immune deficiency syndrome. COPD and asthma are assigned to the chronic pulmonary disease category and are considered a single comorbidity. Because it is possible that some of the study patients were newly diagnosed with a pulmonary condition on the index date, and these pulmonary conditions were not reported as pre-index comorbidities, not all study patients met the CCI criterion for chronic pulmonary disease.
Statistical Analysis
All data transformations and statistical analyses were performed using SAS software, version 9.1 (SAS Institute, Cary, NC). To compare pre-index characteristics between the 2 cohorts, the Pearson chi-square test was used for categorical variables, and the t-test was used for continuous variables. To compare medians, the non-parametric median test was used.
Multivariate regression models were used to adjust for baseline characteristics. The independent variables included age, gender, census region, and CCI score. For the models, we created 3 census regions: Northeast, West, and Midwest/South/ unknown. All 2-way interactions were considered, and only those with significant results were included in the models. Age by region was the only significant interaction included in all models. For the dependent variable of respiratory-related total health cost, analysis of covariance (an extension of ordinary least squares regression) was used, and adjusted means (also known as least squares means) were estimated and compared. We estimated adjusted means by applying into the model the grand means of age and CCI score and the grand proportion of each category of gender and census region. For the dichotomous dependent variable indicating an acute event (i.e., ER use or inpatient hospital use with LOS ≥ 1 day), logistic regression was used and adjusted odds ratios were reported. All statistical tests were 2-sided with a level of significance of 0.05.
■■ Results
Application of the final inclusion criterion of at least 1 pharmacy claim of any type resulted in the exclusion of 10.9% (n = 763)
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of patients in the COPD cohort and 10.1% (n = 207) patients in the COPD + asthma cohort (Figure 2 ). Among the remaining 8,086 patients who met the study criteria, 6,243 (77.2%) were stratified to the COPD cohort and 1,843 (22.8%) to the COPD + asthma cohort. Compared with the COPD cohort, COPD + asthma cohort patients were slightly younger, and a higher percentage was female. Geographic representation also differed between cohorts (P < 0.001), but in both cohorts, approximately 75% of patients were in the northeastern United States, and the geographic location for 12%-13% of the patients was unknown ( Table 2 ).
The COPD + asthma cohort had more comorbidities, with a mean CCI score of 2.6 (standard deviation [SD] ± 2.1) compared with 2.3 [± 2.3] for the COPD cohort (P < 0.001, Table 3 ). Congestive heart failure, chronic pulmonary diseases, rheumatologic disease, peptic ulcer disease, mild-to-moderate diabetes, pneumonia, and acute upper respiratory infections were more prevalent in the COPD + asthma cohort and peripheral vascular disease, and metastatic solid tumors were more prevalent in the COPD cohort. Except for rates of pulmonary disease, these comorbidity differences were slight.
Unadjusted Health Care Utilization and Costs
Unadjusted health care utilization metrics are presented in Table 4 . Respiratory-related resource utilization rates in the COPD + asthma cohort were higher than in the COPD cohort for every utilization metric except total inpatient days. The proportions of patients who received outpatient treatment for COPD exacerbations did not significantly differ by cohort (7.1% for COPD + asthma vs. 7.8% for COPD; P = 0.279). Unadjusted health care costs, including pharmacy, medical, and total (pharmacy + medical), stratified as respiratory-related, not respiratory-related, and all-cause, are presented in Table 5 . Unadjusted mean respiratory-related costs for the post-index period were higher for the COPD + asthma cohort than for the COPD cohort ($7,240 vs. $5,158; P = 0.001). The median allcause health care costs for the post-index period were higher for the COPD + asthma cohort than the COPD cohort ($12,513 vs. $10,146; P < 0.001, Table 5 ). Respiratory-related pharmacy costs were a relatively small part of total respiratory-related health care costs, approximately 5.7% for the COPD cohort and 8.8% for the COPD + asthma cohort. Respiratory-related costs accounted for 22.0% of total health care costs for the COPD cohort and 28.7% for the COPD + asthma cohort. n/a n/a n/a n/a n/a n/a Table 6 ). The COPD + asthma cohort ($7,135; 95% CI, $6,556-$7,714) had higher adjusted respiratory-related total health care costs than did the COPD cohort ($5,204; 95% CI, $4,888-$5,519, P < 0.001; Table 7 ).
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■■ Discussion
Despite the high prevalence and mortality of asthma and COPD, little is known about their combined impact on health care utilization and costs. Our analysis had several interesting findings. Clinical characteristics of the cohorts differed significantly. Compared with the COPD-only cohort, the COPD + asthma cohort was younger, comprised a higher proportion of females, and had a greater burden of comorbidity, evidenced by higher CCI scores and prevalence of select chronic conditions. Our finding that the COPD + asthma cohort comprised a higher proportion of younger and female patients is consistent with the findings of a Centers for Disease Control and Prevention study, which reported that asthma was more often diagnosed in younger and female patients. 21 In our study, patients in the COPD + asthma cohort had a higher prevalence of respiratory-related comorbidities, including congestive heart failure, pneumonia, and upper respiratory infections. After adjusting for differences in demographics and comorbidities, the COPD + asthma cohort was 1.6 times as likely as the COPD cohort to have a respiratoryrelated ER visit or hospitalization. As a result, respiratory-related health care cost was significantly higher in the COPD + asthma cohort than in the COPD cohort. Among enrollees with COPD, an additional diagnosis of asthma was associated with a 37.1% increase in adjusted mean respiratory-related total health care cost. These findings demonstrate the significant economic burden posed by asthma in the presence of COPD.
Many health care organizations have turned to clinical initiatives and disease management programs to better manage patients with prevalent diseases who require frequent and costly health care services. Among patients with COPD, pharmacologic and non-pharmacologic interventions that reduce exacerbations through respiratory-related ER visits and hospitalizations have the potential to generate savings. Although our study did not address this possibility specifically, our findings suggest that it should be explored in future research. Studies have shown that select respiratory treatments such as inhaled corticosteroid and long-acting beta agonist combination products reduce bronchial obstruction and airway inflammation in patients with COPD or asthma treated in outpatient settings, thus reducing ER visits and hospitalizations. [6] [7] [8] When implementing a program, it is important to identify patients with characteristics that place them at risk of incurring more utilization and higher health care costs. Our findings suggest that patients with concomitant COPD and asthma may be an appropriate group for a focused intervention.
Limitations
There are limitations to this study. First, we may have excluded patients with very mild COPD or those who have not been diagnosed, thereby overstating per-patient health care utilization and costs. To ensure that patients had COPD, we required at least 2 medical claims for COPD, and to ensure that the patients had a pharmacy benefit, we required that they had at least 1 pharmacy claim for any medication during a 2-year period of continuous enrollment. About 10% of the patients who otherwise met the inclusion/exclusion criteria were excluded by the absence of at least 1 pharmacy claim for any drug. However, we did not require a pharmacy claim for a respiratory medication; the low median costs for respiratory-related medications suggest that we may have also captured mild COPD patients. In addition, our use of a broad range of respiratory-related diagnoses may have overestimated respiratory-related health care utilization.
Second, users of the IHCIS database are blinded from knowledge of the characteristics of individual health plans in the database, so potentially important characteristics are unknown, 
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such as the presence of annual pharmacy benefit maximum caps and plan coverage of only generic drugs, characteristics that were common among Medicare Advantage plans in 2004. Third, the relationship between COPD and/or asthma severity and study outcomes could not be explored because diagnosis codes do not provide information regarding severity levels.
Third, there are also challenges in differentiating COPD from asthma, particularly among the elderly, and it is possible that some patients may have been misdiagnosed, and therefore stratified incorrectly.
11 Fourth, administrative data are subject to coding errors and omissions, and observational designs are vulnerable to unmeasured factors that may have influenced outcomes. Our low c-statistic and R-squared values suggest that results could be attributable to unmeasured confounding factors. Fifth, our population was primarily from the northeastern United States so our results may not be representative of the entire U.S. population.
Seventh, results of this study reflect health care utilization and cost within our dataset for patients identified by plans as being in the Medicare Advantage program and may not reflect patterns from another population, setting, or plans that submit data on patients not coded as Medicare Advantage participants.
■■ Conclusion
Patients with COPD and asthma use more health care services and incur higher costs than those with COPD without the presence of asthma. These patients may be an appropriate group for a focused intervention to improve disease management and outcomes. 
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